{
  "id": 2838732,
  "title": "StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too",
  "url": "https://urgent.news/2026/08/23/stockwatch-merck-moderna-cancer-vaccine-gives-a-shot-in-the-arm-to",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-23T17:54:35.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/cancer/stockwatch-merck-moderna-cancer-vaccine-gives-a-shot-in-the-arm-to-sequencing-companies-too/"
  },
  "original_language": "en",
  "account": "Merck & Co. (MRK) and Moderna (MRNA) reported what they believed to be the world's first positive Phase III results for their cancer vaccine, a personalized neoantigen therapy called intismeran autogene. This mRNA-based vaccine, when combined with Merck's Keytruda (pembrolizumab), showed greater improvement in both recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) compared to Keytruda alone. Consequently, both company stocks saw a significant increase. Illumina (ILMN), PacBio (PACB), and Oxford Nanopore Technologies (ONT) also experienced a surge in their share prices, benefiting from the sequencing companies' association with the groundbreaking cancer therapy. Illumina's shares climbed 16% to $219.40, PacBio's rose 18% to $1.35, and Oxford Nanopore's soared 39% to £170, all due to the cancer vaccine news. Analysts and biotechnology experts have hailed this development as a \"watershed moment\" and \"landmark win\" for Moderna, predicting a diversification from its COVID-19 vaccine focus.",
  "summary": "Because intismeran autogene is a personalized cancer therapy made for each patient based on the individual genetic mutations of their tumors, the Merck-Moderna stock surge extended to sequencing giants such as Illumina, Pacific Biosciences of California, and to a degree Oxford Nanopore Technologies. The post StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies,…",
  "key_points": [
    "Merck & Moderna's cancer vaccine shows positive Phase III results",
    "Neoantigen therapy intismeran autogene improves RFS and DMFS",
    "Illumina, PacBio, and Oxford Nanopore stocks surge 16%, 18%, and 39%"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}